Cantor Fitzgerald Issues Positive Estimate for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Analysts at Cantor Fitzgerald boosted their FY2024 earnings per share (EPS) estimates for shares of Zevra Therapeutics in a research report issued on Wednesday, January 8th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings of ($1.93) per share for the year, up from their previous estimate of ($1.97). Cantor Fitzgerald has a “Overweight” rating and a $25.00 price objective on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.96) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.04 million. During the same quarter in the prior year, the company earned ($0.40) EPS.

A number of other research firms also recently issued reports on ZVRA. Roth Mkm boosted their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, November 20th. Maxim Group raised their target price on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, September 24th. Canaccord Genuity Group decreased their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Finally, Guggenheim assumed coverage on shares of Zevra Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $20.00 price objective on the stock. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $21.57.

Zevra Therapeutics Stock Performance

Shares of NASDAQ ZVRA opened at $8.53 on Friday. The stock has a market cap of $455.30 million, a price-to-earnings ratio of -4.33 and a beta of 2.01. Zevra Therapeutics has a 12 month low of $4.20 and a 12 month high of $9.76. The company has a 50 day simple moving average of $8.78 and a two-hundred day simple moving average of $7.58. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ZVRA. Vestal Point Capital LP purchased a new stake in shares of Zevra Therapeutics during the third quarter worth approximately $3,644,000. Sanctuary Advisors LLC acquired a new stake in Zevra Therapeutics during the 2nd quarter worth $474,000. Geode Capital Management LLC grew its holdings in shares of Zevra Therapeutics by 14.2% during the third quarter. Geode Capital Management LLC now owns 1,043,864 shares of the company’s stock worth $7,246,000 after buying an additional 129,600 shares in the last quarter. Propel Bio Management LLC acquired a new stake in shares of Zevra Therapeutics in the third quarter valued at about $1,248,000. Finally, Simplify Asset Management Inc. purchased a new position in shares of Zevra Therapeutics in the third quarter worth about $833,000. 35.03% of the stock is owned by hedge funds and other institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.